MRAβ: A multimodal MRI‐derived amyloid‐β biomarker for Alzheimer's disease

Abstract

AbstractFlorbetapir 18F (AV45), a highly sensitive and specific positron emission tomographic (PET) molecular biomarker binding to the amyloid‐β of Alzheimer's disease (AD), is constrained by radiation and cost. We sought to combat it by combining multimodal magnetic resonance imaging (MRI) images and a collaborative generative adversarial networks model (CollaGAN) to develop a multimodal MRI‐derived Amyloid‐β (MRAβ) biomarker. We collected multimodal MRI and PET AV45 data of 380 qualified participants from the ADNI dataset and 64 subjects from OASIS3 dataset. A five‐fold cross‐validation CollaGAN were applied to generate MRAβ. In the ADNI dataset, we found MRAβ could characterize the subject‐level AV45 spatial variations in both AD and mild cognitive impairment (MCI). Voxel‐wise two‐sample t‐tests demonstrated amyloid‐β depositions identified by MRAβ in AD and MCI were significantly higher than healthy controls (HCs) in widespread cortices (p < .05, corrected) and were much similar to those by AV45 (r > .92, p < .001). Moreover, a 3D ResNet classifier demonstrated that MRAβ was comparable to AV45 in discriminating AD from HC in both the ADNI and OASIS3 datasets, and in discriminate MCI from HC in ADNI. Finally, we found MRAβ could mimic cortical hyper‐AV45 in HCs who later converted to MCI (r = .79, p < .001) and was comparable to AV45 in discriminating them from stable HC (p > .05). In summary, our work illustrates that MRAβ synthesized by multimodal MRI could mimic the cerebral amyloid‐β depositions like AV45 and lends credence to the feasibility of advancing MRI toward molecular‐explainable biomarkers.